Lilly’s Oral GLP-1 Pill Cuts Blood Sugar More Than Standard Drugs in Late-Stage Trials
Eli Lilly’s experimental oral GLP-1 drug orforglipron delivered strong blood sugar control in two late-stage trials, showing greater reductions in A1C than rival therapies and promising added weight loss benefits. In head-to-head comparisons, orforglipron reduced A1C by up to 1.7%, outperforming AstraZeneca’s dapagliflozin (0.8%) in patients already on metformin. When combined with insulin glargine, the…